cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
23andme Holding Co
17 own
7 watching
Current Price
$2.51
$0.09
(3.72%)
logo-me
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,143.19M
52-Week High
52-Week High
6.31
52-Week Low
52-Week Low
2.02
Average Volume
Average Volume
1.59M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,143.19M
icon52-Week High6.31
icon52-Week Low2.02
iconAverage Volume1.59M
iconDividend Yield--
iconP/E Ratio--
What does the 23andme Holding Co do?
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Read More
News & Events about 23andme Holding Co.
Globe Newswire
2 months ago
-14 percent of those surveyed say theyre stressed, compared to more than 47 percent in 2020-Under 20 percent of those surveyed said COVID-19 would interfere with their traditional holiday plans; down from 62 percent in 2020-However, most respondents still have some concern about their overall health...
Globe Newswire
2 months ago
The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activitySOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human ...
Globe Newswire
3 months ago
Poster to provide details on study design and expansion phase for ongoing Phase 1 study in patients with advanced solid malignanciesSOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a...
PR Newswire
6 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Missfresh Limited - MF SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Missfresh Limited - MF PR Newswire NEW YORK, July 21, 2022 NEW YORK, July 21, 2022 /PRNewswire/ -- Pomerantz LLP...
Zolmax
6 months ago
Stratos Wealth Partners LTD. boosted its position in 23andMe Holding Co. (NASDAQ:ME Get Rating) by 14.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,695 shares of the companys stock after buying an ...
Frequently Asked Questions
Frequently Asked Questions
What is 23andme Holding Co share price today?
plus_minus_icon
Can Indians buy 23andme Holding Co shares?
plus_minus_icon
How can I buy 23andme Holding Co shares from India?
plus_minus_icon
Can Fractional shares of 23andme Holding Co be purchased?
plus_minus_icon
What are the documents required to start investing in 23andme Holding Co stocks?
plus_minus_icon
What is today’s traded volume of 23andme Holding Co?
plus_minus_icon
What is today’s market capitalisation of 23andme Holding Co?
plus_minus_icon
What is the 52-Week High and Low Range of 23andme Holding Co?
plus_minus_icon
What percentage is 23andme Holding Co down from its 52-Week High?
plus_minus_icon
What percentage is 23andme Holding Co up from its 52-Week Low?
plus_minus_icon
Current Price
$2.51
$0.09
(3.72%)
logo-me
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00